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fDepartment of Pathology and Molecular Medicine, Hamilton Health Sciences, Hamilton, Ontario, CanadaAbstractPurpose: Pneumatosis intestinalis is a radiologic diagnosis that manifests in a variety of clinical settings. We report 4 cases of pneumatosis
intestinalis in patients undergoing cancer treatments that included cytotoxic agents and/or tyrosine kinase inhibitors. These reports aim to
provide insight into the clinical interpretation and pathogenesis of pneumatosis intestinalis in the setting of cancer treatments and demonstrate
a potential association with tyrosine kinase inhibitors.
Methods: Radiologists responsible for the interpretation of adult imaging at our tertiary care centre were surveyed to identify cases of
pneumatosis intestinalis arising in the midst of cancer treatment. The case histories were reviewed by physicians with expertise in cancer
treatment.
Results: Four cases of chemotherapy-related pneumatosis intestinalis were identified. The diagnosis was made in 1 patient during inves-
tigations undertaken for nonelife-threatening abdominal symptoms and incidentally in 2 patients by abdominal imaging used to measure
chemotherapy response. A fourth patient presented in a life-threatening manner, and abdominal imaging was symptom guided. Interestingly,
3 of the 4 patients were receiving treatments that included a tyrosine kinase inhibitor, and this agent was the only identifiable potential
etiology in 1 patient.
Conclusions: The significance of pneumatosis intestinalis arising during cancer treatments is difficult to interpret because of the complex
nature of the diseases and the treatments that often include combinations of cytotoxic agents and/or novel therapies. These reports
demonstrate the importance of classifying this radiologic finding according clinical severity rather than etiology and underscore the need for
continued observation for unexplained adverse effects when using novel therapies.ResumeObjectif : La pneumatose intestinale est un diagnostic radiologique qui se manifeste dans divers contextes cliniques. Nous signalons quatre
cas de pneumatose intestinale chez des patients qui ont des traitements pour le cancer incluant notamment des agents cytotoxiques ou des
inhibiteurs de la tyrosine-kinase. Les cas ont ete signales afin de nous aider a mieux comprendre l’interpretation clinique et la pathogenese de
la pneumatose intestinale dans un contexte de traitement du cancer, et de demontrer un lien possible avec les inhibiteurs de la tyrosine-kinase.
Methodes : Onademande aux radiologistes responsables de l’interpretationdes examensd’imagerie pour adultesdenotre centrede soins tertiaires de
deceler les cas de pneumatose intestinale chez des patients en cours de traitement du cancer. Les dossiers ont ete etudies par des oncologues.
Resultats : Quatre cas de pneumatose intestinale liee a la chimiotherapie ont ete deceles. Un patient a ete diagnostique pendant l’examen de
sympto^mes abdominaux ne mettant pas en danger la vie et deux patients ont ete diagnostiques lors d’examens effectuees afin d’evaluer la* N.V. and K.D. contributed equally to this manuscript.
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313Pneumatosis intestinalis and cancer therapy / Canadian Association of Radiologists Journal 63 (2012) 312e317reponse a la chimiotherapie. Un quatrieme patient s’est presente avec une affection pouvant mettre la vie en danger et l’imagerie abdominale
a ete effectuee en fonction des sympto^mes. Fait interessant, trois des quatre patients recevaient des traitements comprenant un inhibiteur de la
tyrosine-kinase et cet agent etait la seule cause potentiellement definissable chez un patient.
Conclusion : Il est difficile d’interpreter l’importance clinique de la pneumatose intestinale qui se produit pendant le traitement du cancer en
raison de la complexite des pathologies et des traitements, qui regroupent souvent une combinaison d’agents cytotoxiques ou de therapies
nouvelles. Les rapports demontrent l’importance de repertorier ces resultats radiologiques selon la gravite clinique pluto^t que la cause, ainsi
que la necessite de continuer a observer les effets indesirables et non expliques lors de l’utilisation de therapies nouvelles.
 2012 Canadian Association of Radiologists. All rights reserved.
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bowel wall, is a radiologic finding rather than a clinical
diagnosis [1]. Treatment decisions are based on the clinical
presentation rather than the radiologic finding itself. We
present 4 incidences of PI that developed in patients under-
going systemic cancer treatments in which the clinical
scenarios ranged from mild nonelife-threatening presenta-
tions to life-threatening situations. Interestingly, 3 of the
patients were receiving treatments that included tyrosine
kinase inhibitors (tki) in which this relatively new class of
anticancer agents target dysregulated signal transduction
pathways [2]. Recent reports have implicated multitargeted
tki agents in the development of PI [3,4]. However, PI has
not been associated with the use of more-selective tki agents
such as imatinib mesylate used in the treatments described
below. The potential causes and pathogenesis of PI are dis-
cussed in relation to these clinical scenarios, and we explore
the possibility that PI is a class effect of both multitargeted
and selective tki agents.
Clinical CasesCase 1A 29-year-old man with b-thalassemia trait was diagnosed
with chronic myelogenous leukaemia (CML) when he
presented with a white blood cell (WBC) count of 380 109/L
(reference range, 4-11  109/L) and splenomegaly. The
patient was anemic (hemoglobin, 70 g/L), and the platelet
count was normal.
Standard treatment with the selective tki imatinib mesy-
late 400 mg/d was initiated [5]. Twelve weeks later, the
patient described 3 episodes of melena over 1 day. The
abdominal examination was normal, and the patient was
afebrile. The platelet and the absolute neutrophil counts were
normal, as were coagulation parameters. Plain radiographs of
the abdomen revealed PI within the ascending colon without
free intra-abdominal air (Figure 1A). Computed tomography
(CT) of the abdomen detected PI extending from the cecum
to the proximal transverse colon, with collections of extra-
luminal gas anterior to the cecum and the ascending colon
(Figure 1B).
Imatinib was discontinued, and conservative management
was recommended. Blood cultures remained sterile. Plainradiographs obtained 2 weeks later showed a reduction of
intramural gas. The patient underwent an unrelated allogeneic
bone marrow transplantation 156 days after discontinuing
imatinib and died from acute graft-versus-host disease. Sero-
logic studieswere negative for human immunodeficiency virus
1 and 2 and cytomegalovirus.Case 2PI was detected in a 68-year-old woman by CT imaging
undertaken to measure the response of her recurrent renal cell
carcinoma (RCC) to the oral tki sunitinib malate. Comor-
bidities included essential hypertension and chronic obstruc-
tive pulmonary disease. Intravenous contrast agent for CTwas
withheld because of an elevated serum creatinine. PI was seen
within the distal small bowel along with free intraperitoneal
air and dilated loops of bowel (Figure 2). The patient was
asymptomatic and afebrile, and without peritoneal signs but
described anorexia and watery diarrhoea 2 days prior. The
complete blood cell count was normal, urea 21.2 mmol/L
(reference range, 3.0-6.5 mmol/L), and creatinine 481 mmol/L
(reference range, 50-100 mmol/L). Azotemia was related to
the diarrhoea, anorexia, and prior nephrectomy. The patient
was treated briefly with intravenous hydration and antibiotics,
and sunitinib was discontinued. The creatinine decreased and
sunitinib was resumed at a reduced dosage. CT imaging 4
months later revealed resolution of PI and RCC progression.
Sunitinib was discontinued.Case 3PI was detected incidentally by CT imaging in a 48-year-
old man with T-cell non-Hodgkin lymphoma (NHL),
undertaken to measure chemotherapy response. Other
medical conditions included essential hypertension and
dyslipidemia. The patient originally presented with an
abdominal mass and required a transverse colectomy, small
bowel resection, and ileostomy when the diagnosis of NHL
was confirmed. Treatment with systemic chemotherapy,
which included cytotoxic agents and steroids (CHOP
[cyclophosphamide, doxorubicin, vincristine, prednisone]),
was initiated. Six days after starting the fourth cycle (128
days after surgery), CT imaging showed extensive PI in the
distal small bowel loops and extraluminal air anterior to the
Figure 1. Pneumatosis intestinalis developing in a patient diagnosed with chronic myelogenous leukaemia 12 weeks after starting therapy with the tyrosine
kinase inhibitor imatinib. (A) Left lateral decubitus plain radiograph, showing intramural gas (arrowheads) in the ascending colon. (B) Axial computed
tomographic images of the abdomen confirms intramural gas in transverse and ascending colon (arrowhead). (C) Small foci of extraluminal gas (arrow) is
consistent with localized perforation of the colon.
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The patient was asymptomatic. The complete blood cell
count, serum electrolytes, and creatinine were normal.
Surgical intervention was not recommended. The patient
received another 2 cycles of chemotherapy. CT imaging after
the final chemotherapy cycle showed that PI had improved.Case 4A previously healthy 46-year-old man was diagnosed with
Philadelphia chromosome positive acute lymphoblasticFigure 2. Incidental detection of pneumatosis intestinalis in a patient treated with
Axial computed tomographic abdominal images, showing evidence of air within
adjacent mesentery (arrows). Note normal adjacent air and contrast-filled bowel
intestinalis (arrowheads) and free intraperitoneal air (arrows).leukaemia. The WBC count was elevated to 42.2  109/L
and consisted mostly of lymphoblasts. Induction chemo-
therapy with cytotoxic agents and steroids was initiated. The
tki imatinib 600 mg/d was added for the Philadelphia
chromosome positive disease status [6]. Twelve days later,
the patient presented with neutropenic sepsis, which required
intravenous antibiotics, fluids, and vasopressors. Chemo-
therapy agents, including imatinib, were discontinued. The
next day, the patient required tracheal intubation and
mechanical ventilation. Five days later, abdominal distention
was noted. A plain abdominal roentgenogram (Figure 4A)the tyrosine kinase inhibitor sunitinib for recurrent renal cell carcinoma. (A)
the small bowel wall (arrowhead). The air dissects through the walls into the
loops. (B) The coronal computed tomography images, showing pneumatosis
Figure 3. Incidental detection of pneumatosis intestinalis in a patient receiving systemic chemotherapy for enteropathy-associated T-cell non-Hodgkin
lymphoma. (A) Axial computed tomographic (CT) images of the mid abdomen, demonstrating extensive pneumatosis intestinalis (arrowheads) within multiple
loops of small bowel. (B) An inferior-section CT image, showing air tracking along the mesenteric vessels (arrows).
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ascending colon, and lucencies over the liver were consistent
with portal venous gas. CT imaging confirmed PI throughout
the small bowel and stomach, and gas within the portal
venous system, along with dilatation of the jejunum and
transverse colon (Figure 4, B and C). Blood cultures grew
Escherichia coli. The patient’s condition improved without
surgical intervention. Imatinib and systemic chemotherapy
were later resumed without recurrence of PI.Discussion
The detection of PI in the midst of cancer treatment is
difficult to interpret. An early classification system that
groups PI by the mechanism of bowel-wall disruption does
not account for its multifactorial nature in the setting of
systemic cancer treatments and does not guide clinical care
[1]. The radiologic features of PI are variable and often of
limited help in guiding clinical care. For instance, multiple
submucosal and/or subserosal circular cysts are benign
findings, often limited to the colon, known as pneumatosis
cystoides intestinalis (PCI) [7e9]. Linear distribution of gas
within the bowel wall is a nonspecific finding seen in benign
and life-threatening presentations of PI [9,10]. The presence
of hepatic portal gas and PI implies gastrointestinal necrosisTable 1
Summary of the radiologic findings seen in the 4 cases of PIa
Case no. (Figure no.) Plain film radiographs CT images
1 (1) PI without free intra-abdominal air PI in the ascend
with extralum
2 (2) No examination PI within the di
intraperitonea
3 (3) No examination Extensive PI in
extraluminal
4 (4) Dilatation and PI that involve the
small bowel and portal venous gas
PI that involves
and presence
CT ¼ computed tomography; PI ¼ pneumatosis intestinalis.
a All CT examinations were completed on a GE 64-slice volume CT Lightspeed
single, venous-phase, standard-axial, abdominal CT protocol with oral and intra
thickness was 2.5 mm; when used, the CT contrast agent was Omnipaque 300 mthat is often associated with life-threatening clinical
scenarios [11].
More recently, Ho et al [10] classified PI to either benign or
life-threatening clinical presentations and accounts for the
multifactorial nature of PI seen with systemic cancer treat-
ments. This classification places benign presentations of PI
into 8 categories: (i) pulmonary diseases that predispose to
alveolar rupture; (ii) iatrogenic causes; (iii) systemic disorders,
including vasculitis; (iv) hemoglobin disorders; (v) intestinal
disorders that inhibit mucosal defenses or disrupt motility; (vi)
medications, including steroids and chemotherapy agents;
(vii) solid organ and bone marrow transplantation related
infections; and (viii) idiopathic primary pneumatosis and PCI.
Life-threatening presentations of PI include intestinal
ischemia, severe infections, including Clostridium septicum,
direct intestinal trauma, and bone marrow transplantation and
solid organ transplant-related complications.
The first 3 scenarios represent benign presentations of PI,
and the fourth case manifested in a life-threatening manner.
The radiologic features are summarized in Table 1. In the
first case scenario, it is likely PI was related to the tki ima-
tinib. The linear gas pattern and melena excluded PCI.
Infectious agents within the bowel were excluded. Abdom-
inal pain and melena in immunocompromised hosts is
suggestive of C septicum or cytomegalovirus infection.
However, C septicum presents as life-threatening colitis inFollow-up imaging
ing and transverse colon
inal gas
Radiographs 2 wk later showed decrease in PI
stal small bowel and free
l air
CT 4 mo later showed absence of PI
distal small bowel and
air
PI reduced even when chemotherapy
was continued
stomach and small bowel
of portal venous gas
PI resolved without surgical intervention
scanner (GE Medical Systems, Milwaukee, WI); the images are acquired as
venous contrast; coronal reformats were obtained from axial images; slice
g/mL (GE Healthcare, Princeton, NJ).
Figure 4. Pneumatosis intestinalis in a patient with Philadelphia chromosome positive acute lymphoblastic leukaemia that presented with febrile neutropenia
during induction chemotherapy that included the tyrosine kinase inhibitor imatinib. (A) A plain radiograph of the abdomen, revealing multiple loops of small
bowel with linear streaks of air in keeping with bowel pneumatosis (arrowheads). (B) Coronal computed tomographic (CT) abdominal images, depicting
pneumatosis intestinalis (arrowheads) and air in the portal venous system (arrows). (C) The axial CT image, revealing pneumatosis intestinalis (arrowheads)
with air fissuring through to the serosal surface of bowel wall (arrow).
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[12,13]. Serologic tests excluded cytomegalovirus infection.
PI has not been described in the setting of b-thalassemia trait,
a known diagnosis in this patient, but has manifested in the
setting of more-severe hemoglobin disorders [14,15]. There
is a single report of PI in a patient with CML that only
manifested during cytotoxic chemotherapy treatment [16].
Imatinib could potentially cause PI through non-
neutropenic immunosuppressive effects and/or inhibition of
intestinal motility. For instance, imatinib disrupts normal
maturation and antigen presentation capabilities of dendritic
cells, and inhibits T-cell proliferation and function [17].
Imatinib also disrupts normal colonic motility through inhi-
bition of the KIT receptor [18e20].
The second scenario involves PI detected incidentally
during treatment with the tki sunitinib for recurrent RCC.The patient was known to have chronic obstructive pulmo-
nary disease, which is also associated with benign presen-
tations of PI. However, sunitinib has been associated with PI
[3]. The plausible mechanism is inhibition of vascular
endothelial growth factor receptors and subsequent impair-
ment of the regenerative ability of the intestinal mucosa to
repair microperforations [21].
In the third case, PI developed in an asymptomatic patient
during chemotherapy for NHL. PI was not related to the prior
abdominal surgery, given the prolonged time interval, and PI
was not seen on earlier postoperative CT imaging. PI could
have been related to the cytotoxic chemotherapy agents that
damage intestinal mucosa and/or the high doses of steroids
that increase permeability through the bowel wall by
depletion of lymphoid tissue in Peyer patches [1,22]. Despite
the extensive PI, the nonelife-threatening presentation is
317Pneumatosis intestinalis and cancer therapy / Canadian Association of Radiologists Journal 63 (2012) 312e317consistent with Ho et al [10], in which PI is considered as
a benign clinical presentation when solely related to systemic
chemotherapies.
The fourth case underscores the complexity in assigning
PI to a single mechanism in the setting of systemic cancer
treatments. The presence of portal venous gas, however, is
considered an ominous radiologic abnormality that is often
associated with bowel necrosis, and its presence was in
keeping with the life-threatening presentation in this patient
[11]. Mechanical ventilation used to mange the patient’s
hypoxia could have predisposed to PI through alveolar
rupture. The cytotoxic chemotherapy agents and steroids
used for acute lymphoblastic leukaemia treatment were other
potential causes of PI. However, these tend to be associated
with benign presentations of PI, which is not consistent with
this patient’s presentation. Causes of PI listed by Ho et al
[10] that could account for this life-threatening presentation
include neutropenic colitis or intestinal ischemia related to
hypotension and the use of vasopressor agents. The patient
was receiving treatment with the tki agent imatinib at the
time of presentation and was considered a potential
contributing factor. This patient had at least 6 identifiable
conditions known to manifest as PI; this underscores the
importance of classifying PI by clinical presentation.
An interesting finding is that 3 of the 4 patients who pre-
sented developed PI while receiving tki agents. The strongest
association is with the first case, in which all other causes of PI
were excluded. The other 2 cases presented with other condi-
tions that predispose to PI. However, the tki agents cannot be
completely dismissed, given that other unexpected adverse
effects have emerged with this class of anticancer agents since
coming to market [3,23,24]. These cases stress the need for
ongoing vigilance for undocumented adverse effects when
using novel therapies and underscore the complexity of PI
when it develops during systemic cancer therapy.
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